Literature DB >> 9489650

Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation.

P Martin1, R Nash, J Sanders, W Leisenring, C Anasetti, H J Deeg, R Storb, F Appelbaum.   

Abstract

We have undertaken a formal study to evaluate the reproducibility of retrospective assessments for grading the severity of acute GVHD. Using criteria previously established by the Seattle group, three reviewers independently assigned GVHD severity grades for a set of 100 marrow transplant patients. Significant differences were found in the distribution of GVHD grades assigned by one of the reviewers as compared to the other two reviewers. In only 40% of cases did all three reviewers assign the same GVHD grade, and in only 68-71% of cases did all three reviewers assign the same grade within 0-I vs II-IV or 0-II vs III-IV categories. Despite the high rate of disagreement between any two reviewers, at least two reviewers assigned the same overall GVHD grade in 93% of cases. These results suggest that current criteria for assessing the severity of GVHD by a single reviewer are not sufficiently reliable for rigorous clinical studies. As an alternative to the original criteria, we have developed and tested simplified criteria that summarize the clinical course of GVHD as reflected by the progression of disease and the amount of immunosuppressive treatment used to control the disease. Our results suggest that the revised criteria might yield more reproducible retrospective grading than the original criteria. Although the original criteria and the revised criteria might produce different results for individual patients, the overall distributions of grades with the two systems were similar. The proposed revised criteria could be implemented without disrupting the continuity and consistency with previous grading assigned by the original criteria.

Entities:  

Mesh:

Year:  1998        PMID: 9489650     DOI: 10.1038/sj.bmt.1701083

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Urinary elafin and kidney injury in hematopoietic cell transplant recipients.

Authors:  Sangeeta Hingorani; Laura S Finn; Emily Pao; Rick Lawler; Gary Schoch; George B McDonald; Behzad Najafian; Brenda Sandmaier; Ted Gooley
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-11       Impact factor: 8.237

2.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

Authors:  Hesham Eissa; Ted A Gooley; Mohamed L Sorror; Franchesca Nguyen; Bart L Scott; Kristine Doney; Keith R Loeb; Paul J Martin; John M Pagel; Jerry P Radich; Brenda M Sandmaier; E Houston Warren; Rainer Storb; Frederick R Appelbaum; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-06       Impact factor: 5.742

3.  Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.

Authors:  Scott Samuelson; Brenda M Sandmaier; Helen E Heslop; Uday Popat; George Carrum; Richard E Champlin; Rainer Storb; Josef T Prchal; Theodore A Gooley; H Joachim Deeg
Journal:  Br J Haematol       Date:  2011-02-17       Impact factor: 6.998

4.  Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic stem cell transplantation.

Authors:  Hasanain Shikari; Francisco Amparo; Ujwala Saboo; Reza Dana
Journal:  Cornea       Date:  2015-03       Impact factor: 2.651

5.  An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens.

Authors:  Wendy M Leisenring; Paul J Martin; Effie W Petersdorf; Anne E Regan; Nada Aboulhosn; Jean M Stern; Saundra N Aker; Raymond C Salazar; George B McDonald
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

6.  Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.

Authors:  Fabrizio Carnevale-Schianca; Wendy Leisenring; Paul J Martin; Terry Furlong; Gary Schoch; Claudio Anasetti; Frederick R Appelbaum; Paul A Carpenter; H Joachim Deeg; Hans-Peter Kiem; Rainer Storb; George B McDonald; Richard A Nash
Journal:  Biol Blood Marrow Transplant       Date:  2009-06       Impact factor: 5.742

7.  Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Jing Liu; Xiao-Su Zhao; Yan-Rong Liu; Lan-Ping Xu; Xiao-Hui Zhang; Huan Chen; Yu-Hong Chen; Feng-Rong Wang; Wei Han; Yu-Qian Sun; Chen-Hua Yan; Fei-Fei Tang; Xiao-Dong Mo; Kai-Yan Liu; Qiao-Zhen Fan; Xiao-Jun Huang; Ying-Jun Chang
Journal:  Chin Med J (Engl)       Date:  2018-12-05       Impact factor: 2.628

8.  Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.

Authors:  Janghee Woo; Dae Ro Choi; Barry E Storer; Cecilia Yeung; Anna B Halpern; Rachel B Salit; Mohamed L Sorror; David W Woolston; Tim Monahan; Bart L Scott; H Joachim Deeg
Journal:  Haematologica       Date:  2019-07-09       Impact factor: 9.941

9.  Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Jun Kong; Meng-Ge Gao; Ya-Zhen Qin; Yu Wang; Chen-Hua Yan; Yu-Qian Sun; Ying-Jun Chang; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Su Zhao
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.